(19)
(11) EP 1 757 302 A8

(12) CORRECTED EUROPEAN PATENT APPLICATION
published in accordance with Art. 158(3) EPC

(15) Correction information:
Corrected version no 1 (W1 A1)

(48) Corrigendum issued on:
12.12.2007 Bulletin 2007/50

(43) Date of publication:
28.02.2007 Bulletin 2007/09

(21) Application number: 05727594.3

(22) Date of filing: 31.03.2005
(51) International Patent Classification (IPC): 
A61K 38/00(2006.01)
A61P 3/00(2006.01)
A61P 9/00(2006.01)
C12Q 1/02(2006.01)
 A61K 48/00(2006.01)
A61P 3/10(2006.01)
C12N 5/10(2006.01)
G01N 33/15(2006.01)
(86) International application number:
PCT/JP2005/006357
(87) International publication number:
WO 2005/094866 (13.10.2005 Gazette 2005/41)
(84) Designated Contracting States:
AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU MC NL PL PT RO SE SI SK TR

(30) Priority: 31.03.2004 US 557708 P

(71) Applicants:
  • TOUDAI TLO, Ltd.
    Tokyo 113-0033 (JP)
  • Nissan Chemical Industries, Ltd.
    Chiyoda-ku, Tokyo 101-0054 (JP)

(72) Inventors:
  • KADOWAKI, Takashi
    Tokyo 113-0034 (JP)
  • YAMAUCHI, Toshimasa
    Tokyo 113-0024 (JP)
  • KITAJIMA, Shoko c/o Mitsubishi Pharma Corporation
    Tokyo 103-8405 (JP)
  • ITO, Yusuke c/o Biological Research Laboratories Nissan Chemical Industries, Ltd.
    Minamisaitama-gun, Saitama 349-0294 (JP)

(74) Representative: Dehmel, Albrecht 
Dehmel & Bettenhausen Patentanwälte, Herzogspitalstrasse 11
80331 München
80331 München (DE)

   


(54) ADIPONECTIN EXPRESSION INDUCER AND UTILIZATION OF THE SAME


(57) The present invention provides adiponectin expression-inducing agents, and therapeutic agents using the same for obesity and obesity-related diseases such as cardiovascular diseases or metabolic diseases, as well as methods of searching for adiponectin expression-inducing agents.
KLF9, which can bind to the 32-bp fragment of position -188 to position -157 from the adiponectin expression start site, was demonstrated to enhance adiponectin promoter activity.
Therefore, the present invention uses KLF9 as an adiponectin expression-inducing agent, and suggests that KLF9 replenishment therapy is useful for preventing and/or treating obesity or obesity-related diseases including metabolic diseases such as insulin resistance and type II diabetes, and cardiovascular diseases.